Cosmo Pharmaceuticals NV
SIX:COPN
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
43.8
116.6
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CHF.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| IE |
|
Cosmo Pharmaceuticals NV
SIX:COPN
|
1.8B CHF |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
1T USD |
Loading...
|
|
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
528.2B USD |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
275.2B CHF |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
210.8B GBP |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.8T DKK |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
220.9B CHF |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
269.2B USD |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD |
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
145.4B USD |
Loading...
|
Market Distribution
| Min | -6 913.1% |
| 30th Percentile | 0% |
| Median | 3.1% |
| 70th Percentile | 10.2% |
| Max | 197.7% |
Other Profitability Ratios
Cosmo Pharmaceuticals NV
Glance View
Cosmo Pharmaceuticals NV, rooted in the picturesque landscapes of Italy but with its headquarters in Ireland for strategic financial maneuvering, has carved a niche for itself within the global pharmaceuticals industry. This specialty pharmaceutical company is dedicated to the development and manufacturing of therapies for gastrointestinal diseases. Cosmo’s forte lies in its proprietary clinical development platform, providing innovative solutions aimed at enhancing gastrointestinal health, covering conditions like inflammatory bowel disease, colon infections, and bowel preparation for colonoscopy. These critical health areas require specialized treatments, and Cosmo leverages its technological prowess through its novel drug delivery technologies such as Methylene Blue MMX and Aemcolo. This focus not only elevates the scientific community’s understanding of GI issues but positions Cosmo at the intersection of research innovation and practical treatment efficacy. Cosmo Pharmaceuticals thrives on a business model that seeks to maximize the potential of its intellectual property and licensing operations. By investing substantially in research and development, the company brings forward its proprietary products which offer targeted therapies, and then participates in strategic partnerships and licensing agreements with larger pharmaceutical companies. By doing so, Cosmo reduces risk and diversifies its revenue channels. This agile strategy allows them to earn royalties and revenue through commercialization deals, placing them in a financial position of strength without having to shoulder the full burden of global marketing and distribution. The company’s ability to merge scientific ingenuity with strategic business acumen underscores its journey from a regional player to a notable name on the international pharmaceutical stage.
See Also
Net Margin is calculated by dividing the Net Income by the Revenue.
The current Net Margin for Cosmo Pharmaceuticals NV is 32.7%, which is above its 3-year median of 22.3%.
Over the last 3 years, Cosmo Pharmaceuticals NV’s Net Margin has decreased from 45.1% to 32.7%. During this period, it reached a low of -12.5% on Dec 31, 2023 and a high of 53.2% on Dec 31, 2024.